<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="271">
  <stage>Registered</stage>
  <submitdate>24/08/2005</submitdate>
  <approvaldate>26/08/2005</approvaldate>
  <actrnumber>ACTRN12605000232639</actrnumber>
  <trial_identification>
    <studytitle>Dose Response Study of a Complementary Medicine Formulation in Primary Hypercholesterolaemia</studytitle>
    <scientifictitle>Dose Response Studyto determine the efficacy and safety of a Complementary Medicine Formulation, in tablet form, for lowering lipid levels in primary Hypercholesterolaemia by comparing baseline levels of lipids with post treatment lipid levels.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Primary Hypercholesterolaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cynara scolymus:
One arm took one tablet of the study medication twice a day (morning and evening with meals) and the other arm took two tablets twice a day (morning and evening with meals).</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in fasting serum low-density lipoprotein (LDL) cholesterol level from baseline to end of treatment.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in fasting serum levels of total cholesterol.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in high-density lipoprotein cholesterol (HDL).</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in triglycerides.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in apolipoproteins B and A-1.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Coenzyme Q10 and homocysteine.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>LDL cholesterol 3.5 and 5.7mmol/L2. Body mass index 32kg/m23. Subject is willing to cease all medications over the course of the study, excluding medications for acute conditions such as pain or dyspepsia. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Individuals with triglyceride levels &gt;4mmol/L2. Individuals with a total cholesterol level &gt;10 mmol/L3. Individuals with clinically abnormal liver function tests at baseline (measured at visit 2). 4. Women who are pregnant or unwilling to use birth control for the period of the study. 5.Individuals with diabetes6. Individuals with hyperthyroidism. 7.Individuals with obstructive bile duct disease. 8.Individuals with metabolic disorders other than primary hypercholesterolaemia, including phytosterolaemia. 9.Individuals who smoke. 10.Individuals with cardiovascular disease. 11.Subjects unwilling to comply with the study protocols. 12.Subjects with poor venous access. 13.Any other condition which in the opinion of the researchers could compromise the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants were assigned by a first come first recruited basis. The tablets were supplied in numbered containers by the sponsors.</concealment>
    <sequence>Subjects were assigned to the treatment groups by coin toss after initial recruitment.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>9/10/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Pathways</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Pathways</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a two arm open comparison of two different dosage regimes undertaken in a homogeneous population comparing baseline measurements with effects of treatment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross University HUman Researh Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joan O'Connor</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203649</phone>
      <fax>+61 2 66203307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Stephen Myers</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203403</phone>
      <fax>+61 2 66203307</fax>
      <email>smyers@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>